Levy B, Bollaert P E, Charpentier C, Nace L, Audibert G, Bauer P, Nabet P, Larcan A
Réanimation Médicale Polyvalente, Hôpital Central, Nancy, France.
Intensive Care Med. 1997 Mar;23(3):282-7. doi: 10.1007/s001340050329.
To compare the effects of norepinephrine and dobutamine to epinephrine on hemodynamics, lactate metabolism, and gastric tonometric variables in hyperdynamic dopamine-resistant septic shock.
A prospective, intervention, randomized clinical trial.
Adult medical/surgical intensive care unit in a university hospital.
30 patients with a cardiac index (CI) > 3.51 x min(-1) x m(-2) and a mean arterial pressure (MAP) < or = 60 mmHg after volume loading and dopamine 20 microg/kg per min and either oliguria or hyperlactatemia.
Patients were randomized to receive an infusion of either norepinephrine-dobutamine or epinephrine titrated to obtain an MAP greater than 80 mmHg with a stable or increased CI.
Baseline measurements included: hemodynamic and tonometric parameters, arterial and mixed venous gases, and lactate and pyruvate blood levels. These measurements were repeated after 1, 6, 12, and 24 h. All the patients fulfilled the therapeutic goals. No statistical difference was found between epinephrine and norepinephrine-dobutamine for systemic hemodynamic measurements. Considering metabolic and tonometric measurements and compared to baseline values, after 6 h, epinephrine infusion was associated with an increase in lactate levels (from 3.1 +/- 1.5 to 5.9 +/- 1.0 mmol/l;p < 0.01), while lactate levels decreased in the norepinephrine-dobutamine group (from 3.1 +/- 1.5 to 2.7 +/- 1.0 mmol/l). The lactate/pyruvate ratio increased in the epinephrine group (from 15.5 +/- 5.4 to 21 +/- 5.8; p < 0.01) and did not change in the norepinephrine-dobutamine group (13.8 +/- 5 to 14 +/- 5.0). Gastric mucosal pH (pHi) decreased (from 7.29 +/- 0.11 to 7.16 +/- 0.07; p < 0.01) and the partial pressure of carbon dioxide (PCO2) gap (tonometer PCO2-arterial PCO2) increased (from 10 +/- 2.7 to 14 +/- 2.7 mmHg; p < 0.01) in the epinephrine group. In the norepinephrine-dobutamine group pHi (from 7.30 +/- 0.11 to 7.35 +/- 0.07) and the PCO2 gap (from 10 +/- 3.0 to 4 +/- 2.0 mmHg) were normalized within 6 h (p < 0.01). The decrease in pHi and the increase in the lactate/pyruvate ratio in the epinephrine group was transient, since it returned to normal within 24 h.
Considering the global hemodynamic effects, epinephrine is as effective as norepinephrine-dobutamine. Nevertheless, gastric mucosal acidosis and global metabolic changes observed in epinephrine-treated patients are consistent with a markedly inadequate, although transient, splanchnic oxygen utilization. The metabolic and splanchnic effects of the combination of norepinephrine and dobutamine in hyperdynamic dopamine-resistant septic shock appeared to be more predictable and more appropriate to the current goals of septic shock therapy than those of epinephrine alone.
比较去甲肾上腺素联合多巴酚丁胺与肾上腺素对高动力型多巴胺抵抗性感染性休克患者血流动力学、乳酸代谢及胃张力测定指标的影响。
一项前瞻性、干预性、随机临床试验。
一所大学医院的成人内科/外科重症监护病房。
30例患者,在液体复苏及静脉输注多巴胺20μg/(kg·min)后,心脏指数(CI)>3.51L/(min·m²),平均动脉压(MAP)≤60mmHg,且存在少尿或高乳酸血症。
将患者随机分为两组,分别接受去甲肾上腺素联合多巴酚丁胺或肾上腺素输注,根据血压调整剂量,使MAP>80mmHg,CI稳定或升高。
基线测量指标包括血流动力学和张力测定参数、动脉血和混合静脉血气、血乳酸和丙酮酸水平。在1、6、12和24小时后重复测量。所有患者均达到治疗目标。在全身血流动力学测量方面,肾上腺素与去甲肾上腺素联合多巴酚丁胺之间未发现统计学差异。就代谢和张力测定指标而言,与基线值相比,输注肾上腺素6小时后,乳酸水平升高(从3.1±1.5mmol/L升至5.9±1.0mmol/L;p<0.01),而去甲肾上腺素联合多巴酚丁胺组乳酸水平降低(从3.1±1.5mmol/L降至2.7±1.0mmol/L)。肾上腺素组乳酸/丙酮酸比值升高(从15.5±5.4升至21±5.8;p<0.01),去甲肾上腺素联合多巴酚丁胺组则无变化(从13.8±5升至14±5.0)。肾上腺素组胃黏膜pH值(pHi)降低(从7.29±0.11降至7.16±0.07;p<0.01),二氧化碳分压(PCO₂)差值(胃张力计PCO₂-动脉血PCO₂)增大(从10±2.7mmHg升至14±2.7mmHg;p<0.01)。去甲肾上腺素联合多巴酚丁胺组pHi(从7.30±0.11升至7.35±0.07)及PCO₂差值(从10±3.0mmHg降至4±2.0mmHg)在6小时内恢复正常(p<0.01)。肾上腺素组pHi降低及乳酸/丙酮酸比值升高是短暂的,24小时内恢复正常。
就整体血流动力学效应而言,肾上腺素与去甲肾上腺素联合多巴酚丁胺效果相当。然而,接受肾上腺素治疗的患者出现胃黏膜酸中毒及整体代谢变化,这与内脏氧利用明显不足(尽管是短暂的)相符。在高动力型多巴胺抵抗性感染性休克中,去甲肾上腺素联合多巴酚丁胺的代谢及内脏效应似乎比单独使用肾上腺素更具可预测性,更符合目前感染性休克治疗的目标。